IL125953A0 - Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy - Google Patents

Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy

Info

Publication number
IL125953A0
IL125953A0 IL12595398A IL12595398A IL125953A0 IL 125953 A0 IL125953 A0 IL 125953A0 IL 12595398 A IL12595398 A IL 12595398A IL 12595398 A IL12595398 A IL 12595398A IL 125953 A0 IL125953 A0 IL 125953A0
Authority
IL
Israel
Prior art keywords
administering
methods
receptor antagonists
dopamine agonist
ampa receptor
Prior art date
Application number
IL12595398A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL125953A0 publication Critical patent/IL125953A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12595398A 1997-09-05 1998-08-27 Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy IL125953A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5796597P 1997-09-05 1997-09-05

Publications (1)

Publication Number Publication Date
IL125953A0 true IL125953A0 (en) 1999-04-11

Family

ID=22013812

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12595398A IL125953A0 (en) 1997-09-05 1998-08-27 Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy

Country Status (11)

Country Link
US (1) US20010034345A1 (fr)
EP (1) EP0900567A3 (fr)
JP (1) JP3547624B2 (fr)
KR (1) KR100457756B1 (fr)
AU (1) AU8319398A (fr)
CA (1) CA2246560C (fr)
HU (1) HUP9802022A2 (fr)
IL (1) IL125953A0 (fr)
NZ (1) NZ331636A (fr)
TW (1) TW490304B (fr)
ZA (1) ZA988009B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs Systemtech Elektromotorische Antriebseinheit
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
EP1604654A1 (fr) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
AU2006234627C1 (en) * 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
DK2010184T3 (da) * 2006-04-06 2013-03-25 Nupathe Inc Implatanter til behandlingen af dopamin associerede tilstande
WO2008041118A2 (fr) 2006-10-04 2008-04-10 Pfizer Products Inc. Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
WO1992013535A1 (fr) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
EA002905B1 (ru) * 1996-05-15 2002-10-31 Пфайзер Инк. 2,3-двузамещенные-4(3н)-хиназолиноны и содержащая их фармацевтическая композиция

Also Published As

Publication number Publication date
CA2246560C (fr) 2002-12-17
HUP9802022A2 (hu) 1999-05-28
KR19990029528A (ko) 1999-04-26
EP0900567A2 (fr) 1999-03-10
JP3547624B2 (ja) 2004-07-28
EP0900567A3 (fr) 2001-05-02
CA2246560A1 (fr) 1999-03-05
NZ331636A (en) 2000-08-25
JPH11139991A (ja) 1999-05-25
ZA988009B (en) 2000-03-22
KR100457756B1 (ko) 2005-04-14
US20010034345A1 (en) 2001-10-25
HU9802022D0 (en) 1998-10-28
AU8319398A (en) 1999-03-18
TW490304B (en) 2002-06-11

Similar Documents

Publication Publication Date Title
HUP9802021A3 (en) Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
EP1027011A4 (fr) Administration d'agents actifs, notamment d'agonistes et antagonistes du recepteur de 5-ht, afin de traiter l'ejaculation precoce
IL114116A0 (en) Delivery of therapeutic agents to receptors using polysaccharides
WO2004058717A8 (fr) Derives d'isoquinolinone et leur utilisation comme agents therapeutiques
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
WO2001005763A3 (fr) Composes possedant une activite sur les recepteurs muscariniques
AU2002300464A1 (en) Apoliprotein A-I Agonist And Their Use To Treat Dyslipidemic Disorders
IL126747A0 (en) Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
PL353854A1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
PL341114A1 (en) Antagonists of thrombosin receptors
IL125953A0 (en) Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
SG83723A1 (en) Novel therapeutic agents that modulate 5ht receptors
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
IL143385A0 (en) 5ht1 antagonists for antidepressant therapy
IL206567A0 (en) Use of an agonist to the igs4 neuromdin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or activity of the igs4 neuromedin receptor ploypeptide
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
HUP0201405A2 (en) Pharmaceutical composition for therapeutic use of melatonin
AU2002300534A1 (en) Methods of Administering an AMPA Receptor Antagonist to Treat Dyskinesias Associated with Dopamine Agonist Therapy
WO2000076500A8 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
AU2193797A (en) Delivery of therapeutic agents to the prostate
WO2001046198A3 (fr) Antagonistes de recepteur opioide kappa non peptidiques
ZA98484B (en) Use of beta3-adrenergic receptor agonists for the preparation of healing drugs
AU8553898A (en) Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system